

Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic inflammation in airway mucosa in mice

David Goldblatt

The University of Texas Rio Grande Valley, david.goldblatt01@utrgv.edu

Gabriella Valverde Ha

The University of Texas MD Anderson Cancer Center

Shradha Wali

The University of Texas MD Anderson Cancer Center

Vikram V. Kulkarni

The University of Texas MD Anderson Cancer Center

Michael K. Longmire

The University of Texas MD Anderson Cancer Center

See next page for additional authors

Follow this and additional works at: <https://scholarworks.utrgv.edu/colloquium>



Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Goldblatt, David; Valverde Ha, Gabriella; Wali, Shradha; Kulkarni, Vikram V.; Longmire, Michael K.; Jaramillo, Ana M.; Chittuluru, Rosha P.; Fouts, Adrienne; Martinez-Moczygemba, Margarita; and Lei, Jonathan T., "Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic inflammation in airway mucosa in mice" (2024). *Research Colloquium*. 7.
<https://scholarworks.utrgv.edu/colloquium/2023/posters/7>

This Poster is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in Research Colloquium by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu, william.flores01@utrgv.edu.

Author Information

David Goldblatt, Gabriella Valverde Ha, Shradha Wali, Vikram V. Kulkarni, Michael K. Longmire, Ana M. Jaramillo, Rosha P. Chittuluru, Adrienne Fouts, Margarita Martinez-Moczygemba, and Jonathan T. Lei

Epithelial Immunomodulation by Aerosolized Toll-like Receptor Agonists Attenuates Allergic Responsiveness in Mice

David L. Goldblatt^{1,4,5,*}, Gabriella Valverde Ha¹, Shradha Wali¹, Vikram V. Kulkarni¹, Michael K. Longmire¹, Ana M. Jaramillo¹, Rosha P. Chittuluru¹, Adrienne Fouts¹, Margarita Martinez-Moczygemba^{2,3}, Jonathan T. Lei³, David P. Huston^{2,3}, Michael J. Tuvim¹, Burton F. Dickey¹, Scott E. Evans^{1,*}

¹Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.

²Department of Microbial and Molecular Pathogenesis, Texas A&M Health Science Center, Houston, Texas, 77030, USA.

³Clinical Science and Translational Research Institute, Texas A&M Health Science Center, Houston, Texas, 77030, USA.

⁴Howard Hughes Medical Institute, Chevy Chase, MD, 20815 USA.

⁵University of Texas Rio Grande Valley School of Medicine, Edinburg, TX, 78539

Background

Allergic asthma is a chronic inflammatory respiratory disease associated with eosinophilic infiltration, increased mucus production, airway hyperresponsiveness (AHR), and airway remodeling. Epidemiologic data has revealed that the prevalence of allergic sensitization and associated diseases has increased in the twentieth century. This has been hypothesized to be partly due to reduced contact with microbial organisms (the hygiene hypothesis) in industrialized society. Airway epithelial cells, once considered a static physical barrier between the body and the external world, are now widely recognized as immunologically active cells that can initiate, maintain, and restrain inflammatory responses, such as those that mediate allergic disease. Airway epithelial cells can sense allergens via myriad expression of Toll-like receptors (TLRs) and other pattern-recognition receptors (PRRs).

Methods

We sought to determine whether the innate immune response stimulated by a combination of Pam2CSK4 ("Pam2", TLR2/6 ligand) and a class C oligodeoxynucleotide ODN362 ("ODN", TLR9 ligand) when delivered together by aerosol ("Pam2ODN"), can modulate the allergic immune response to allergens.

Results

Treatment with Pam2ODN 7 days before sensitization to House Dust Mite (HDM) extract resulted in a strong reduction in eosinophilic and lymphocytic inflammation. This Pam2ODN immunomodulatory effect was also seen using Ovalbumin (OVA) and *A. oryzae* (Ao) mouse models.

Conclusion

The immunomodulatory effect was observed as much as 30 days before sensitization to HDM, but ineffective just 2 days after sensitization, suggesting that Pam2ODN immunomodulation lowers the allergic responsiveness of airway epithelial cells. Furthermore, Pam2 and ODN cooperated synergistically suggesting that this treatment is superior to any single agonist in the setting of allergen immunotherapy.